• linkedin
  • Increase Font
  • Sharebar

    Laser retains limited role for management of RVO-related ME


    Subthreshold technique

    Subthreshold grid laser treatment of macular edema secondary to BRVO was compared with continuous wave grid laser to see if the former procedure that is performed with a micropulse diode laser might reduce complications [Ophthalmology. 2006;113(12):2237-2242].

    The results from the randomized trial showed macular edema improved rapidly with the conventional laser technique, but overall improvements in visual acuity and macular edema were similar in the two treatment groups. There were no biomicroscopic or angiographic signs of laser treatment in the subthreshold group.

    Another study compared subthreshold grid laser with bevacizumab (Avastin, Genentech) in eyes with recurrent macular edema after conventional grid laser treatment [Graefes Arch Clin Exp Ophthalmol. 2015;253(10):1647-1651]. The results, both functional and anatomic, clearly favored anti-VEGF therapy in this setting, Dr. Bandello said.


    Targeting the periphery

    Laser treatment of peripheral ischemia is based on the idea that it would eliminate VEGF production by nonperfused retina. Various investigators have reported on this approach with conflicting results.

    A small study by Rick Spaide, MD, showed panretinal photocoagulation of peripheral areas of retinal vascular nonperfusion in eyes with CRVO had no benefit for improving visual acuity or decreasing anti-VEGF injection burden [Retina. 2013;33(1):56-62].

    Similar results were achieved in the RELATE trial, which randomized patients with CRVO or BRVO treated for 24 weeks with anti-VEGF therapy to continue as needed monthly injections alone or combined with scatter and grid laser photocoagulation [Ophthalmology. 2015;122(7):1426-1437]. It found the addition of laser treatment had no long-term functional or anatomic benefits, nor did it reduce anti-VEGF treatment burden, Dr. Bandello said.

    In contrast, Tomomatsu et al. reported that retinal photocoagulation of non-perfused peripheral retina in eyes with ischemic BRVO prevented recurrence of macular edema after intravitreal anti-VEGF therapy [Acta Ophthalmol. 2016;94(3):e225-230]. 


    Francesco Bandello, MD

    E: [email protected]

    This article was adapted from a presentation that Dr. Bandello presented at the 2017 World Retina Congress. Dr. Bandello is an advisory board member for companies marketing products used for the treatment of macular edema secondary to RVO.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow

    var script= ' ';